brought to you byLaboratorio Nacional de Engenharia Civil – LNEC
Skip main navigation
CommentaryFree Access

Emerging therapeutic nanotechnologies in pancreatic cancer: advances, risks and challenges

    Ana Rebelo

    CBIOS, Universidade Lusófona de Humanidades e Tecnologias, Department of Sciences & Health Technologies (ECTS), Campo Grande 376, 1749-024 Lisboa, Portugal

    Department of Biomedical Sciences, Faculty of Pharmacy, University of Alcalá, Ctra. A2 km 33,600 Campus Universitario, 28871 Alcalá de Henares, Spain

    Search for more papers by this author

    &
    Catarina Reis

    *Author for correspondence:

    E-mail Address: catarinareis@ff.ulisboa.pt

    iMed. ULisboa – Faculdade de Farmácia, Department of Galenic Pharmacy and Pharmaceutical Technology (DFGTF), Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal

    IBEB, Faculdade de Ciências, Universidade de Lisboa, 1749-016 Lisboa, Portugal

    Search for more papers by this author

    Published Online:2 Oct 2018https://doi.org/10.4155/tde-2018-0048
    Free first page

    References

    • 1 Teague A, Lim KH, Wang-Gillam A. Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. Ther. Adv. Med. Oncol. 7(2), 68–84 (2015).Crossref, Medline, CAS, Google Scholar
    • 2 Manzur A, Oluwasanmi A, Moss D, Curtis A, Hoskins C. Nanotechnologies in pancreatic cancer therapy. Pharmaceutics 9(4), 39 (2017).Crossref, Google Scholar
    • 3 Rebelo A, Molpeceres J, Rijo P, Reis CP. Pancreatic cancer therapy review: from classic therapeutic agents to modern nanotechnologies. Curr. Drug Metab. 18(4), 346–359 (2017).Crossref, Medline, CAS, Google Scholar
    • 4 Zhou J, Lindsey E, Stojadinovic A et al. Incidence rates of exocrine and endocrine pancreatic cancers in the United States. Cancer Causes Control 21(6), 853–861 (2010).Crossref, Medline, Google Scholar
    • 5 Zhu Q, Pan X, Sun Y et al. Biological nanoparticles carrying the Hmda-7 gene are effective in inhibiting pancreatic cancer in vitro and in vivo. PLoS ONE 12(10), 1–12 (2017).Crossref, Google Scholar
    • 6 Birhanu G, Javar HA, Seyedjafari E, Zandi-Karimi A. Nanotechnology for delivery of gemcitabine to treat pancreatic cancer. Biomed. Pharmacother. 88, 635–643 (2017).Crossref, Medline, CAS, Google Scholar
    • 7 Sielaff CM, Mousa SA. Status and future directions in the management of pancreatic cancer: potential impact of nanotechnology. J. Cancer Res. Clin. Oncol. 144(7), 1205–1217 (2018).Crossref, Medline, CAS, Google Scholar
    • 8 Hackeng WM, Hruban RH, Offerhaus GJA, Brosens LAA. Surgical and molecular pathology of pancreatic neoplasms. Diagn. Pathol. 11(47), 1–17 (2016).Medline, Google Scholar
    • 9 Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J. Gastroenterol. 22(44), 9694–9705 (2016).Crossref, Medline, Google Scholar
    • 10 Karanikas M, Esempidis A, Tzoutze Memet Chasan Z et al. Pancreatic cancer from molecular pathways to treatment opinion. J. Cancer 7(10), 1328–1339 (2016).Crossref, Medline, CAS, Google Scholar
    • 11 Collisson EA, Olive KP. Pancreatic cancer: progress and challenges in a rapidly moving field. Cancer Res. 77(5), 1060–1062 (2017).Crossref, Medline, CAS, Google Scholar
    • 12 Sinha R. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther. 5(8), 1909–1917 (2006).Crossref, Medline, CAS, Google Scholar
    • 13 Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 66, 2–25 (2014).Crossref, Medline, CAS, Google Scholar
    • 14 ud Din F, Aman W, Ullah I et al. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int. J. Nanomedicine 12, 7291–7309 (2017).Crossref, Medline, CAS, Google Scholar
    • 15 Alexis F, Rhee JW, Richie JP, Radovic-Moreno AF, Langer R, Farokhzad OC. New frontiers in nanotechnology for cancer treatment. Urol. Oncol. 26(1), 74–85 (2008).Crossref, Medline, CAS, Google Scholar
    • 16 McCarroll J, Teo J, Boyer C, Goldstein D, Kavallaris M, Phillips PA. Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer. Front. Physiol. 5(2), 1–10 (2014).Medline, Google Scholar
    • 17 Adiseshaiah PP, Crist RM, Hook SS, McNeil SE. Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nat. Rev. Clin. Oncol. 13(12), 750–765 (2016).Crossref, Medline, CAS, Google Scholar
    • 18 Bisht S, Mizuma M, Feldmann G et al. Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc™) blocks tumor growth and metastases in preclinical models of pancreatic cancer. Mol. Cancer Ther. 9(8), 2255–2264 (2011).Crossref, Google Scholar
    • 19 Ventola CL. The nanomedicine revolution: part 3: regulatory and safety challenges. P T 37(11), 631–639 (2012).Medline, Google Scholar
    • 20 Ventola CL. Progress in nanomedicine: approved and investigational nanodrugs. P T 42(12), 742–755 (2017).Medline, Google Scholar